AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37625587
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose esomeprazole
Trial: 37625814
Drug: TQB2450 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off)
Trial: 37626367
Drug: Camrelizumab combined
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab combined with radiotherapy as neoadjuvant therapy
Trial: 37629366
Drug: No-CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-CPAP treatment (control)
Trial: 37629638
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a class I pullulan-based medical device, applied two times daily.
Trial: 37629671
Drug: Intramuscular Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular Electrical Stimulation
Trial: 37631885
Drug: Ad26.ZEBOV, MVA-BN-Filo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses with a 56-day interval)
Trial: 37632201
Drug: Zibotentan 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 0.25 mg/dapagliflozin 10 mg QD
Trial: 37632201
Drug: Zibotentan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 1.5 mg/dapagliflozin 10 mg QD
Trial: 37632201
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg QD alone
Trial: 37632240
Drug: Epinephrine/adrenaline injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine/adrenaline injection
Trial: 37632240
Drug: Auto-injector prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-injector prescription
Trial: 37632455
Drug: Outpatient oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient oral diuretic intensification
Trial: 37632455
Drug: Expanded composite
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Expanded composite end point (cardiovascular death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification)
Trial: 37632469
Drug: Alirocumab (PCSK9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (PCSK9 inhibitor)
Trial: 37632592
Drug: Carfilzomib (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (10, 15, or 20 mg/m2) in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide)
Trial: 37632656
Drug: 24-hour/day foslevodopa/foscarbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250 mg of LD per 24 hours)
Trial: 37632942
Drug: ASICA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASICA intervention (digital health care intervention providing monthly prompts for TSSE and access to a dermatology nurse)
Trial: 37633156
Drug: Venetoclax 100
RxNorm normalized name: venetoclax 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 100 mg daily from days 1-21, Itraconazole 100 mg twice daily from days 1-21, Azacitidine 100 mg subcutaneously once daily from days 1-7
Trial: 37633275
Drug: Intermediate MRG-001
RxNorm normalized name: neurospora intermedia allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate MRG-001 dose
Trial: 37633589
Drug: LNG 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG 52 mg IUD
Trial: 37634135
Drug: Catheter ablation
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation and guideline-directed medical therapy
Trial: 37634145
Drug: ECLS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECLS plus usual medical treatment
Trial: 37634145
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual medical treatment alone)
Trial: 37634234
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (DXM20)
Trial: 37634234
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care 6 mg dose of dexamethasone (DXMSoC)
Trial: 37634517
Drug: Immediate isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate isoniazid preventive therapy (28 weeks isoniazid [300 mg daily], then placebo until week 40 after delivery)
Trial: 37634517
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (placebo until week 12 after delivery, then isoniazid [300 mg daily] for 28 weeks)
Trial: 37634517
Drug: Immediate isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate isoniazid preventive therapy
Trial: 37634629
Drug: anti-PD-1 inhibitor
RxNorm normalized name: anti-inhibitor coagulant complex 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 inhibitor in combination with standard systemic treatment
Trial: 37634655
Drug: Anti-factor Xa
RxNorm normalized name: Innohep, 20,000 anti-Factor Xa intl units/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-factor Xa NOAC (apixaban 5 mg twice per day, edoxaban 60 mg daily, or rivaroxaban 20 mg daily for 12 months)
Trial: 37634655
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 75 mg daily indefinitely (control group)
Trial: 37634707
Drug: Continuing SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing SGLT2 inhibitors in patients with HF and eGFR <25 mL/min/1.73 m²
Trial: 37635769
Drug: Night-time only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time only subcutaneous apomorphine infusion
Trial: 37635815
Drug: Induction systemic
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction systemic therapy with doublet or triplet chemotherapy plus targeted therapy
Trial: 39445322
Drug: E-BPO cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-BPO cream, 5%
Trial: 37636296
Drug: Pre- and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and/or postconditioning treatment in addition to conventional percutaneous coronary intervention
Trial: 37637060
Drug: Interval debulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval debulking surgery after neoadjuvant chemotherapy (IDS/NAC)
Trial: 37637501
Drug: TAE-iNKT (Transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAE-iNKT (Transarterial Embolization with biweekly iNKT cell infusion)
Trial: 37637501
Drug: TAE (Transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAE (Transarterial Embolization without iNKT cell infusion)
Trial: 37637850
Drug: Transcutaneous afferent
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous afferent patterned stimulation (TAPS) therapy, unsupervised at-home sessions twice daily for four weeks
Trial: 37637850
Drug: Transcutaneous afferent
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous afferent patterned stimulation (TAPS) therapy
Trial: 37637935
Drug: M8891 (7-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M8891 (7-80 mg once daily in 21-day cycles)
Trial: 37638077
Drug: i.v. fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fentanyl 25 μg
Trial: 37638196
Drug: Endovascular Treatment
RxNorm normalized name: Drug coated peripheral artery endovascular stent graft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular Treatment (EVT)
Trial: 39648617
Drug: Atogepant 60
RxNorm normalized name: atogepant 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 60 mg once-daily
Trial: 37638435
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (LDRT) 24 cGy/6 fractions
Trial: 37638435
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (LDRT) 300 cGy/6 fractions
Trial: 37638435
Drug: Sham radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham radiation therapy (0 cGy/6 fractions)
Trial: 37638695
Drug: Muvalaplin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin (30 mg to 800 mg daily for 14 days)
Trial: 37638695
Drug: Muvalaplin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin (single ascending dose of 1 mg to 800 mg)
Trial: 37638695
Drug: Muvalaplin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muvalaplin (multiple ascending dose)
Trial: 37638882
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of treatment options
Trial: 37638882
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of treatment options offered
Trial: 37638882
Drug: Treatment goal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment goal rankings
Trial: 37638882
Drug: Variability in
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variability in treatment goal importance
Trial: 37638882
Drug: Most important
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Most important treatment goal
Trial: 37638968
Drug: 12-month edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month edoxaban treatment
Trial: 37638968
Drug: 3-month edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month edoxaban treatment
Trial: 37639169
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg intravenously every 3 weeks for 12 months
Trial: 37639169
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg q3w
Trial: 37639259
Drug: Mavacamten (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten (2.5 mg once daily for 30 weeks)
Trial: 37639601
Drug: Nicotinic acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinic acetylcholine receptor agonist
Trial: 37639777
Drug: Gaboxadol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol (0.125 mg/kg to 0.24 mg/kg based on weight)
Trial: 37639820
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or oral targeted therapy
Trial: 37639820
Drug: Active cancer
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active cancer treatment
Trial: 37640025
Drug: anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 antibody plus anti-vascular endothelial growth factor receptor 2 inhibitors and eribulin
Trial: 37640455
Drug: Medical grade
RxNorm normalized name: Skarcade Medical Grade Silicone Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical grade honey (L-Mesitran, treatment)
Trial: 37640625
Drug: Anakinra 100mg
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 100mg daily subcutaneous dose during hospitalization
Trial: 37640809
Drug: Enteral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L-citrulline supplementation (100 mg/kg/day) for 7 days
Trial: 37640809
Drug: Enteral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L-citrulline supplementation (200 mg/kg/day) for 7 days
Trial: 37640809
Drug: Enteral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L-citrulline supplementation (300 mg/kg/day) for 7 days
Trial: 37640860
Drug: Bivalent variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent variant vaccines
Trial: 37640860
Drug: Monovalent variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent variant vaccines
Trial: 37640889
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of maternal age, vaginal bleeding, CRL, and hCG
Trial: 37641136
Drug: FX06 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX06 (400 mg/d, for 5 days)
Trial: 37641555
Drug: Aneurysm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aneurysm treatment <6 h after rupture
Trial: 37641555
Drug: Aneurysm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aneurysm treatment 6-24 h after rupture
Trial: 37641586
Drug: Active Intradermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Intradermal Acupuncture combined with SSRIs (AIA)
Trial: 37641586
Drug: Sham Intradermal
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Intradermal Acupuncture combined with SSRIs (SIA)
Trial: 37641586
Drug: Selective Serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Serotonin Reuptake Inhibitors (SSRIs)-only group
Trial: 37642032
Drug: Post-PCI fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-PCI fractional flow reserve measurement after drug-eluting stent implantation; identified adverse clinical characteristics include age ≥65 years, diabetes, chronic kidney disease, left ventricular ejection fraction <50%; identified adverse vessel characteristics include post-PCI fractional flow reserve ≤0.80 and total stent length ≥54 mm.
Trial: 37643290
Drug: Combination HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HIV prevention strategies implemented at the community level
Trial: 37643382
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg once every 3 weeks) combined with bevacizumab and six cycles of chemotherapy doublet
Trial: 37643382
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with bevacizumab and six cycles of chemotherapy doublet
Trial: 37643392
Drug: Weekly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly phone counseling sessions with bidirectional text messages
Trial: 37643392
Drug: Weekly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly phone counseling sessions with unidirectional text messages
Trial: 37643520
Drug: LDL-C Q1
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C Q1 (≤1.76 mmol/L)
Trial: 37643520
Drug: LDL-C Q2
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C Q2 (1.77-2.36 mmol/L)
Trial: 37643520
Drug: LDL-C Q3
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C Q3 (2.37-2.93 mmol/L)
Trial: 37643520
Drug: LDL-C Q4
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C Q4 (>2.93 mmol/L)
Trial: 37643848
Drug: Volatile organic
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile organic compounds (VOCs) in exhaled air analyzed by gas chromatography time-of-flight mass spectrometry
Trial: 37643847
Drug: IPL combined
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL combined with 3% diquafosol ophthalmic solution (IPL+)
Trial: 37643847
Drug: DQS (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DQS (3% diquafosol ophthalmic solution eye-drops) (active control group)
Trial: 37643887
Drug: 4,500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,500 mg of IV semorinemab every 4 weeks for 48 or 60 weeks
Trial: 37644354
Drug: BRIGHT (brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRIGHT (brief cognitive behavioral therapy)
Trial: 37644869
Drug: Calcipotriol/betamethasone in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol/betamethasone in combination with NBUVB
Trial: 37644980
Drug: Intradialytic regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic regional cerebral oxygenation (rSO2) monitoring during the first 72 hours of continuous kidney replacement therapy or throughout each session of intermittent hemodialysis.
Trial: 37645440
Drug: Clinical pharmacist-led
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist-led intervention for drug-related problems
Trial: 37645622
Drug: Tusamitamab ravtansine
RxNorm normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tusamitamab ravtansine at 170 mg/m²
Trial: 37645622
Drug: Tusamitamab ravtansine
RxNorm normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tusamitamab ravtansine at 100 mg/m²
Trial: 37645940
Drug: Remote telehealth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote telehealth Transitional Pain Service (TPS) with opioid-tapering CBT protocol
Trial: 37646148
Drug: rurioctocog alfa
RxNorm normalized name: Rurioctocog alfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rurioctocog alfa pegol (on-demand treatment)
Trial: 37646214
Drug: Transcatheter edge-to-edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge-to-edge repair with the MitraClip device plus maximally tolerated guideline-directed medical therapy (GDMT)
Trial: 37646657
Drug: Melflufen 30
RxNorm normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melflufen 30 mg plus dexamethasone and daratumumab
Trial: 37646657
Drug: Melflufen 40
RxNorm normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melflufen 40 mg plus dexamethasone and daratumumab
Trial: 37646659
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles)
Trial: 37646670
Drug: Lisocabtagene maraleucel
RxNorm normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed, 4-1BB CAR T-cell product administered at a total target dose of 100×10⁶ CAR+ T cells.
Trial: 37646678
Drug: Two-antibody method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-antibody method (EBNA1-IgA and VCA-IgA)
Trial: 37646678
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of P85-Ab and two-antibody method
Trial: 37646702
Drug: Mezigdomide plus
RxNorm normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezigdomide plus dexamethasone (1.0 mg once daily for 21 days, followed by 7 days off, in each 28-day cycle)
Trial: 37646988
Drug: 8000 IU
RxNorm normalized name: Ergocalciferol 8000 IU/1 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8000 IU daily with a loading dose of 50,000 IU
Trial: 37646988
Drug: Standard-of-care control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care control dose (600 IU daily)
Trial: 37646988
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 50,000 IU
Trial: 37647317
Drug: VRVF device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRVF device (self-administered remote visual field monitoring)
Trial: 37647601
Drug: Vibecotamab (XmAb14045)
RxNorm normalized name: Vibecotamab
DrugBank: Vibecotamab (DB18872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibecotamab (XmAb14045) at a target dose of 0.75 μg/kg or higher (n=87)
Trial: 37647728
Drug: TQB2450 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 plus anlotinib 10 mg
Trial: 37647728
Drug: TQB2450 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 plus anlotinib 12 mg
Trial: 37648383
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g azithromycin
Trial: 37648393
Drug: Azithromycin administered
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin administered concurrently with the first and third doses of pentavalent vaccines (Penta-1/3)